Since its creation, Diabeloop has been involving people living with Type 1 diabetes and their families. They have contributed to the development alongside engineers and healthcare professionals. The ease of use and intuitive interfaces of personalized solutions developed by Diabeloop is really inspired by patients and their personal experiences.
In November 2018, Diabeloop’s first medical device, DBLG1, was CE marked. We are working on commercializing, in Europe (France and Germany at first) and later in North America. To support our international ambition and our Research and Development roadmap, we completed a Series B round of funding, setting a European fundraising record for therapeutic artificial intelligence.
Diabeloop developed a self-learning algorithm that embeds therapeutic artificial intelligence, to automate Type 1 diabetes treatment. It is intended to relieve people affected by this chronic condition from having to make constant therapeutic decisions every day and night and to allow them to live life without interruption.
B2C
101 to 250
Series C
$129M
Scaling Up
2015
Health Care Facilities & Hospitals
Type 1 Diabetes Treatment
Therapeutic Decisions
Increase Productivity
Increase Efficiency
Analytics
Service
Yes
Active
Machine Learning
Machine Perception
Natural Language Processing
Automated Planning and Search
Software
Want to work at Diabeloop?
We can introduce you to the right person at Diabeloop
3
1
$75M
Company was founded 2015 and it took almost 7 years (Jun 2022) to raise first external round
Interested in researching Diabeloop?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Diabeloop
Erik Huneker
co-founder and CEO
Dr. Guillaume Charpentier
Founder, Chief Medical Officer
Catherine Dunand
President of the board
Capucine Quil
Head Of Global Marketing
Cecile Ferracci
Chief Commercial Officer
Delphine Piotraut
Head Of Legal
Interested in what they do or partnership?
Learn more about how they work